EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
16 déc. 2022 16h01 HE
|
EyePoint Pharmaceuticals, Inc.
WATERTOWN, Mass., Dec. 16, 2022 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to help improve...
EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
16 nov. 2022 07h00 HE
|
EyePoint Pharmaceuticals, Inc.
WATERTOWN, Mass., Nov. 16, 2022 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to help improve...
EyePoint Pharmaceuticals Announces Participation at Upcoming Investor Conferences
07 nov. 2022 08h00 HE
|
EyePoint Pharmaceuticals, Inc.
WATERTOWN, Mass., Nov. 07, 2022 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to improve the...
EyePoint Pharmaceuticals Reports Third Quarter 2022 Financial Results and Highlights Recent Corporate Developments
02 nov. 2022 07h00 HE
|
EyePoint Pharmaceuticals, Inc.
– Initiated Phase 2 DAVIO 2 clinical trial for wet age-related macular degeneration (wet AMD) and Phase 2 PAVIA clinical trial for non-proliferative diabetic retinopathy (NPDR) – – Presented positive...
EyePoint Pharmaceuticals to Report Third Quarter 2022 Financial Results on November 2, 2022
26 oct. 2022 07h00 HE
|
EyePoint Pharmaceuticals, Inc.
WATERTOWN, Mass., Oct. 26, 2022 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to improve the...
EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
17 oct. 2022 07h00 HE
|
EyePoint Pharmaceuticals, Inc.
WATERTOWN, Mass., Oct. 17, 2022 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to help improve...
EyePoint Pharmaceuticals Announces First Patient Dosed in Phase 2 PAVIA Clinical Trial of EYP-1901 for the Treatment of Non-Proliferative Diabetic Retinopathy
29 sept. 2022 07h00 HE
|
EyePoint Pharmaceuticals, Inc.
WATERTOWN, Mass., Sept. 29, 2022 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to improve the...
EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
16 sept. 2022 07h00 HE
|
EyePoint Pharmaceuticals, Inc.
WATERTOWN, Mass., Sept. 16, 2022 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to help improve...
EyePoint Pharmaceuticals Announces Participation at Upcoming Investor Conferences
06 sept. 2022 16h01 HE
|
EyePoint Pharmaceuticals, Inc.
WATERTOWN, Mass., Sept. 06, 2022 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to improve the...
EyePoint Pharmaceuticals Reports Second Quarter 2022 Financial Results and Highlights Recent Corporate Developments
03 août 2022 07h00 HE
|
EyePoint Pharmaceuticals, Inc.
– First patient dosed in the Phase 2 DAVIO 2 clinical trial for wet age-related macular degeneration (wet AMD) – – Presented positive twelve-month safety and efficacy data from Phase 1 DAVIO clinical...